Metastatic Cancer Treatment Market Trends
The increasing patient pool for cancer as well as the rising geriatric population and life expectancy are expected to be the major factors for the growth of the market. Pharmaceutical giants such as Roche and Novartis are investing in the R&D for the development of innovative and improved medication for the treatment of the disease. Rising interest in the biologics medication especially monoclonal antibodies is also expected to fuel the growth of the market.
The increasing patient pool for cancer as well as the rising geriatric population and life expectancy are expected to be the major factors for the growth of the market. Pharmaceutical giants such as Roche and Novartis are investing in the R&D for the development of innovative and improved medication for the treatment of the disease. Rising interest in the biologics medication especially monoclonal antibodies is also expected to fuel the growth of the market.
- TAGS
- healthcare-industry
- healtcareit
- healtcare
- news
- bisresearch
- lung-cancer-drugs-market
- lung-cancer-market
- colorectal-cancer-market
- prostate-cancer-market
- melanoma-market
- melanoma-treatment-market
- oncology-drugs-market
- cancer-treatment-market
- oncology-market
- breast-cancer-market
- metastasis-cancer-market
- metastatic-cancer-market
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
GLOBAL METASTATIC CANCER TREATMENT MARKET<br />
Focus on Drugs, Competitive Landscape, and Country - Analysis and Forecast (2018-2025)<br />
Key Questions Answered in the Report:<br />
100+<br />
COMPANIES<br />
RESEARCHED<br />
ACROSS THE<br />
VALUE CHAIN<br />
• What are the major market drivers, challenges, and opportunities in the global metastatic<br />
cancer treatment market?<br />
• What are the market shares of the leading segments and sub-segments of the global<br />
metastatic cancer treatment market in 2018 and 2025?<br />
• How will each segment of the global metastatic cancer treatment market grow during the<br />
METICULOUS<br />
COMPILATION OF<br />
MORE THAN 700<br />
RESEARCH HOURS<br />
forecast period, and what will be the revenue generated by each of the segments by the<br />
end of 2025?<br />
• What are the influencing factors that may affect the market share of the key players?<br />
• What are the key developmental strategies implemented by the key players to stand out<br />
in this market?<br />
EXCLUSIVE<br />
INSIGHTS FROM<br />
IN-DEPTH EXPERT<br />
INTERVIEWS<br />
CONTAINS 51<br />
MARKET DATA<br />
TABLES AND<br />
212 FIGURES<br />
SPREAD CROSS<br />
377 PAGES<br />
• How has the market been segmented based on therapeutic indication?<br />
• Which therapeutic indication segment has the largest share and the fastest growth rate<br />
in the global metastatic cancer treatment market?<br />
• Which product segment is expected to register the highest CAGR for the metastatic<br />
cancer treatment market?<br />
• Which geographical location will contribute to the highest sales of the metastatic cancer<br />
treatment drugs during the forecast period?<br />
sales@bisresearch.com www.bisresearch.com 1
TABLE OF CONTENTS<br />
MARKET OVERVIEW<br />
MARKET DYNAMICS<br />
INDUSTRY INSIGHTS<br />
COMPETITIVE LANDSCAPE<br />
GLOBAL METASTATIC CANCER<br />
TREATMENT MARKET BY<br />
THERAPEUTIC APPLICATION<br />
GLOBAL METASTATIC CANCER<br />
TREATMENT MARKET BY<br />
PRODUCT<br />
GLOBAL METASTATIC CANCER<br />
TREATMENT MARKET BY REGION<br />
• Introduction to <strong>Cancer</strong><br />
• <strong>Cancer</strong> Statistics: Incidence,<br />
Survival, and Mortality<br />
• Metastasis and <strong>Metastatic</strong><br />
<strong>Cancer</strong><br />
• Global <strong>Market</strong><br />
• FDA Approvals of Oncology<br />
Drugs<br />
• Assumptions and Limitation<br />
• <strong>Market</strong> Dynamics: Impact<br />
Analysis<br />
• <strong>Market</strong> Drivers<br />
• <strong>Market</strong> Restraints<br />
• <strong>Market</strong> Opportunities<br />
• Introduction<br />
• Regulatory Scenario<br />
• Regulatory Designations<br />
• Patent Landscape<br />
• Introduction<br />
• Key Developments and Strategies<br />
• Porter’s Five Forces Analysis<br />
• <strong>Market</strong> Share (2014-2017)<br />
• Pipeline Analysis<br />
• Overview<br />
• Breast <strong>Cancer</strong><br />
• Melanoma<br />
• Prostate <strong>Cancer</strong><br />
• Lung <strong>Cancer</strong><br />
• Colorectal <strong>Cancer</strong><br />
• Other <strong>Cancer</strong>s<br />
• Overview<br />
• Role of Branded Medicines in<br />
Oncology<br />
• Role of Generic Medicines in<br />
Oncology<br />
• Sales of Oncology Drugs<br />
• Overview<br />
• North America<br />
• Europe<br />
• Asia Pacific<br />
• Latin America<br />
• Rest of the World<br />
REPORT SCOPE AND<br />
METHODOLOGY<br />
■ Scope of the Report<br />
■ Global <strong>Metastatic</strong> <strong>Cancer</strong><br />
<strong>Treatment</strong> <strong>Market</strong><br />
Segmentation<br />
■ Research Methodology<br />
■ Assumptions and<br />
Limitations<br />
■ Data and Prediction<br />
Modelling<br />
COMPANY PROFILES<br />
■ AbbVie, Inc.<br />
■ Amgen, Inc.<br />
■ AstraZeneca PLC<br />
■ Bayer AG<br />
■ Boehringer Ingelheim<br />
International GmbH<br />
■ BRISTOL-MYERS SQUIBB<br />
COMPANY<br />
■ CELGENE CORPORATION<br />
■ Eli-Lilly and Company<br />
■ F. Hoffmann-La Roche AG<br />
■ JOHNSON & JOHNSON<br />
■ Merck & Co., Inc.<br />
■ Novartis AG<br />
■ Pfizer, Inc.<br />
■ SANOFI<br />
■ Takeda Pharmaceutical<br />
Company Limited<br />
■ bluebird bio, Inc.<br />
■ Clovis Oncology, Inc.<br />
■ IDERA PHARMACEUTICALS,<br />
INC.<br />
■ eTheRNA immunotherapies<br />
NV<br />
VIEW COMPLETE<br />
TABLE OF CONTENTS<br />
sales@bisresearch.com www.bisresearch.com 2
LIST OF TABLES<br />
1 Total Regional Geriatric Population by Region<br />
(%), 2015 and 2030<br />
2 Impact of <strong>Market</strong> Drivers<br />
3 Impact of <strong>Market</strong> Restraints<br />
4 <strong>Market</strong> Share (2014-2017)<br />
5 Estimated New Cases and Estimated Deaths in<br />
2018 as per American <strong>Cancer</strong> Society<br />
6 GLOBOCAN Data as of 2012<br />
7 Common sites of Metastasis for <strong>Cancer</strong>s<br />
8 Common Classes of Drugs Under Different<br />
<strong>Cancer</strong> Therapies<br />
9 Recent FDA Approvals of Oncology Drugs<br />
10 Impact of <strong>Market</strong> Drivers<br />
11 Impact of <strong>Market</strong> Restraints<br />
12 Comparison of R&D Expense 2017 and 2016<br />
13 Recent Approval of <strong>Metastatic</strong> <strong>Cancer</strong> Drugs<br />
14 Side Effects Caused by common <strong>Metastatic</strong><br />
<strong>Cancer</strong> Drugs<br />
15 Regulatory Scenario Across the World<br />
16 Regulatory Designations Across The World<br />
17 Patent Landscape<br />
18 Factors Affecting the Bargaining Power of<br />
Suppliers<br />
19 Factors Affecting the Bargaining Power of Buyer<br />
20 Factors Affecting Threat of New Entrant<br />
21 Factors Affecting the Threat of Substitute<br />
22 Factors Affecting the Intensity of Competitive<br />
Rivalry<br />
23 <strong>Market</strong> Share of Key Players (2014-2017)<br />
24 Pipeline Analysis of <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong><br />
Drugs<br />
25 Estimated Incidence, Mortality, and Prevalence of<br />
Breast <strong>Cancer</strong> Worldwide in 2012<br />
26 Estimated Incidence and Mortality of Melanoma<br />
Worldwide in 2012<br />
27 Estimated Incidence, Mortality and Prevalence of<br />
Prostate <strong>Cancer</strong> Worldwide in 2012<br />
28 Estimated Incidence, Mortality and Prevalence of<br />
Lung <strong>Cancer</strong> (for both sexes) Worldwide in 2012<br />
29 Estimated Incidence, Mortality and Prevalence of<br />
Colorectal <strong>Cancer</strong> (for both sexes) Worldwide in<br />
2012<br />
30 Estimated Incidence, Mortality and Prevalence of<br />
Different <strong>Cancer</strong> (for both sexes) Worldwide in<br />
2012<br />
31 List of Companies and Drugs for Various<br />
Therapeutic Indication<br />
32 List of Common Brand-name Drugs used to treat<br />
<strong>Metastatic</strong> <strong>Cancer</strong><br />
33 List of Common Generic Drugs used to treat<br />
<strong>Metastatic</strong> <strong>Cancer</strong><br />
34 Sales of Oncology Drugs<br />
35 State-wise distribution of <strong>Cancer</strong> in India<br />
36 List of Tier 1 and Tier 2 Companies<br />
37 AbbVie Inc.: Recent Developments<br />
38 Amgen, Inc.: Recent Developments<br />
39 AstraZeneca PLC: Recent Developments<br />
40 Bayer AG: Recent Developments<br />
41 Boehringer Ingelheim International GmbH:<br />
Recent Developments<br />
42 BRISTOL-MYERS SQUIBB COMPANY: Recent<br />
Developments<br />
43 CELGENE CORPORATION: Recent Developments<br />
44 Eli-Lilly and Company: Recent Developments<br />
45 F. Hoffmann-La Roche AG: Recent Developments<br />
46 JOHNSON & JOHNSON: Recent Developments<br />
47 Merck & Co.,Inc. : Recent Developments<br />
48 Novartis AG: Recent Developments<br />
49 Pfizer, Inc.: Recent Developments<br />
50 SANOFI: Recent Developments<br />
51 Takeda Pharmaceutical Company Limited: Recent<br />
Developments<br />
sales@bisresearch.com www.bisresearch.com 3
LIST OF FIGURES<br />
1 Common <strong>Treatment</strong>s of <strong>Cancer</strong><br />
2 Global <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong><br />
($Million)<br />
3 Global <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong> by<br />
Therapeutic Indication, 2017<br />
4 Global <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong> by<br />
Therapeutic Indication, 2025<br />
5 Global <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong> by<br />
Products, 2017<br />
6 Global <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong> By<br />
Products, 2025<br />
7 Global <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong> by<br />
Region, 2017<br />
8 Global <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong> Drug<br />
Delivery <strong>Market</strong> by Region, 2025<br />
9 Causes of <strong>Cancer</strong><br />
10 Common Mechanism of Metastasis<br />
11 Types of <strong>Metastatic</strong> <strong>Cancer</strong> (based on how far it<br />
has spread)<br />
12 Global <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2016-2025 ($ Million)<br />
13 <strong>Market</strong> Dynamics: Drivers, Restraints &<br />
Opportunities<br />
14 Targeted Therapies Designed for Different <strong>Cancer</strong><br />
Types<br />
15 Industry Insights (January 2014-February 2018)<br />
16 Competitive Landscape (January 2014-February<br />
2018)<br />
17 Share of Key Developments and<br />
Strategies(January 2014 to March 2018)<br />
18 Product Approvals by Companies<br />
19 Clinical Study, by Companies<br />
20 Product Approvals by Companies<br />
21 Porter’s Five Forces Analysis<br />
22 Types of <strong>Metastatic</strong> <strong>Cancer</strong> by Therapeutic<br />
Indication<br />
23 Global <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong> by<br />
Therapeutic Indication, 2014-2025 ($Million)<br />
24 Signs and Symptoms of <strong>Metastatic</strong> Breast <strong>Cancer</strong><br />
25 Common Molecular Subtypes of Breast <strong>Cancer</strong><br />
26 Global <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong> by<br />
Breast <strong>Cancer</strong>, 2014-2025 ($ Million)<br />
27 List of Common <strong>Metastatic</strong> Breast <strong>Cancer</strong> Drugs<br />
28 Signs and Symptoms of <strong>Metastatic</strong> Melanoma<br />
29 Global <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong> by<br />
Melanoma <strong>Cancer</strong>, 2014-2025 ($ Million)<br />
30 List of Common <strong>Metastatic</strong> Melanoma <strong>Cancer</strong><br />
Drugs<br />
31 Signs and Symptoms of <strong>Metastatic</strong> Prostate<br />
<strong>Cancer</strong><br />
32 Global <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong> by<br />
Prostate <strong>Cancer</strong>, 2014-2025 ($ Million)<br />
33 List of Common <strong>Metastatic</strong> Prostate <strong>Cancer</strong><br />
Drugs<br />
34 Signs and Symptoms of <strong>Metastatic</strong> Lung <strong>Cancer</strong><br />
35 Global <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong> by<br />
NSCLC, 2014-2025 ($ Million)<br />
36 List of Common <strong>Metastatic</strong> Lung <strong>Cancer</strong> Drugs<br />
37 Signs and Symptoms of <strong>Metastatic</strong> Colorectal<br />
<strong>Cancer</strong><br />
38 Global <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong> by<br />
Colorectal <strong>Cancer</strong>, 2014-2025 ($ Million)<br />
39 List of Common <strong>Metastatic</strong> Colorectal <strong>Cancer</strong><br />
Drugs<br />
40 Global <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong> by<br />
Other <strong>Cancer</strong>s, 2014-2025 ($ Million)<br />
41 Classification of Anti-<strong>Cancer</strong> Drugs by Pharma<br />
Class<br />
42 Global <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong> by<br />
Branded Medicines, 2014-2025 ($ Million)<br />
43 Global <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong> by<br />
Generic Medicines, 2014-2025 ($ Million)<br />
44 Global <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong> by<br />
Region, 2014-2025 ($Million)<br />
45 North America <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong><br />
<strong>Market</strong>, 2014-2025 ($Million)<br />
46 North America <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong><br />
<strong>Market</strong> by Country, 2014-2025 ($Million)<br />
47 <strong>Cancer</strong> Patient Data by <strong>Cancer</strong>s Type in the U.S.<br />
(2016)<br />
48 <strong>Cancer</strong> Patient Data by <strong>Cancer</strong>s Type in Canada<br />
(2016)<br />
49 The U.S. <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2014-2025 ($million)<br />
50 Canada <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2014-2025 ($million)<br />
51 Europe <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
sales@bisresearch.com www.bisresearch.com 4
2014-2025 ($Million)<br />
52 Europe <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong> by<br />
Country, 2014-2025 ($Million)<br />
53 <strong>Cancer</strong> Patient Data by <strong>Cancer</strong>s Type in Germany<br />
(2016)<br />
54 <strong>Cancer</strong> Patient Data by <strong>Cancer</strong>s Type in France<br />
(2016)<br />
55 <strong>Cancer</strong> Patient Data by <strong>Cancer</strong>s Type in Italy<br />
(2016)<br />
56 France <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2014-2025 ($million)<br />
57 Germany <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2014-2025 ($million)<br />
58 Italy <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>, 2014-<br />
2025 ($million)<br />
59 Netherland <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2014-2025 ($million)<br />
60 Switzerland <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2014-2025 ($million)<br />
61 The U.K. <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2014-2025 ($million)<br />
62 Spain <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2014-2025 ($million)<br />
63 Sweden <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2014-2025 ($million)<br />
64 Austria <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2014-2025 ($million)<br />
65 Belgium <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2014-2025 ($million)<br />
66 Denmark <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2014-2025 ($million)<br />
67 Finland <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2014-2025 ($million)<br />
68 Poland <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2014-2025 ($million)<br />
69 Russia <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2014-2025 ($million)<br />
70 Ireland <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2014-2025 ($million)<br />
71 Rest of Europe <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong><br />
<strong>Market</strong>, 2014-2025 ($million)<br />
72 Asia Pacific <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2014-2025 ($Million)<br />
73 Asia Pacific <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong><br />
by Country, 2014-2025 ($Million)<br />
74 <strong>Cancer</strong> Patient Data by <strong>Cancer</strong>s Type in China<br />
(2016)<br />
75 <strong>Cancer</strong> Patient Data by <strong>Cancer</strong>s Type in Japan<br />
(2016)<br />
76 <strong>Cancer</strong> Patient Data by <strong>Cancer</strong>s Type in India<br />
(2016)<br />
77 China <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2014-2025 ($million)<br />
78 Japan <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2014-2025 ($million)<br />
79 India <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2014-2025 ($million)<br />
80 South Korea <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong><br />
<strong>Market</strong>, 2014-2025 ($million)<br />
81 Australia <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2014-2025 ($million)<br />
82 Bangladesh <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2014-2025 ($million)<br />
83 Malaysia <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2014-2025 ($million)<br />
84 New Zealand <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong><br />
<strong>Market</strong>, 2014-2025 ($million)<br />
85 Rest of Asia Pacific <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong><br />
<strong>Market</strong>, 2014-2025 ($million)<br />
86 Latin America <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong><br />
<strong>Market</strong>, 2014-2025 ($Million)<br />
87 Latin America <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong><br />
<strong>Market</strong> by Country, 2014-2025 ($Million)<br />
88 Brazil <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2014-2025 ($million)<br />
89 Mexico <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2014-2025 ($million)<br />
90 Argentina <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2014-2025 ($million)<br />
91 Rest of Latin America <strong>Metastatic</strong> <strong>Cancer</strong><br />
<strong>Treatment</strong> <strong>Market</strong>, 2014-2025 ($million)<br />
92 Rest of the World (RoW) <strong>Metastatic</strong> <strong>Cancer</strong><br />
<strong>Treatment</strong> <strong>Market</strong>, 2014-2025 ($Million)<br />
93 Rest of the World (RoW) <strong>Metastatic</strong> <strong>Cancer</strong><br />
<strong>Treatment</strong> <strong>Market</strong> by Country, 2014-2025<br />
($Million)<br />
94 Saudi Arabia <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong><br />
<strong>Market</strong>, 2014-2025 ($million)<br />
95 UAE <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>, 2014-<br />
2025 ($million)<br />
96 South Africa <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong><br />
<strong>Market</strong>, 2014-2025 ($million)<br />
97 Israel <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2014-2025 ($million)<br />
sales@bisresearch.com www.bisresearch.com 5
98 Other <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong>,<br />
2014-2025 ($million)<br />
99 Contribution of Various companies<br />
100 AbbVie Inc.: Overall Product Portfolio<br />
101 AbbVie Inc.: Product Portfolio for <strong>Metastatic</strong><br />
<strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong><br />
102 AbbVie Inc.: Overall Financials (2014-2017)<br />
103 AbbVie Inc.: Revenue by Geography (2014-<br />
2017)<br />
104 AbbVie Inc.: Global Presence<br />
105 AbbVie Inc.: SWOT Analysis<br />
106 Amgen, Inc.: Overall Product Portfolio<br />
107 Amgen, Inc.: Product Portfolio for <strong>Metastatic</strong><br />
<strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong><br />
108 Amgen, Inc. : Overall Financials (2014-2017)<br />
109 Amgen, Inc. : Revenue by Geography (2014-<br />
2017)<br />
110 Amgen, Inc.: Global Presence<br />
111 Amgen, Inc. : SWOT Analysis<br />
112 AstraZeneca PLC: Overall Product Portfolio<br />
113 AstraZeneca PLC: Product Portfolio for <strong>Metastatic</strong><br />
<strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong><br />
114 AstraZeneca PLC: Overall Financials (2014-2017)<br />
115 AstraZeneca PLC: Revenue by Product Sales<br />
(2014-2017)<br />
116 AstraZeneca PLC: Revenue by Geography (2014-<br />
2017)<br />
117 AstraZeneca PLC: Global Presence<br />
118 AstraZeneca PLC: SWOT Analysis<br />
119 Bayer AG: Overall Product Portfolio<br />
120 Bayer AG: Product Portfolio for <strong>Metastatic</strong> <strong>Cancer</strong><br />
<strong>Treatment</strong> <strong>Market</strong><br />
121 Bayer AG: Overall Financials (2014-2017)<br />
122 Bayer AG: Revenue by Geography (2014-2017)<br />
123 Bayer AG: Revenue by Business Segment (2014-<br />
2015)<br />
124 Bayer AG: Revenue by Buisness Segment (2016-<br />
2017)<br />
125 Bayer AG: Global Presence<br />
126 Bayer AG: SWOT Analysis<br />
127 Boehringer Ingelheim International GmbH:<br />
Overall Product Portfolio<br />
128 Boehringer Ingelheim International GmbH:<br />
Product Portfolio for <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong><br />
<strong>Market</strong><br />
129 Boehringer Ingelheim International GmbH:<br />
Overall Financials (2014-2017)<br />
130 Boehringer Ingelheim International GmbH:<br />
Revenue by Geography (2014-2017)<br />
131 Boehringer Ingelheim International GmbH:<br />
Revenue by Business Segment (2014-2015)<br />
132 Boehringer Ingelheim International GmbH:<br />
Revenue by Buisness Segment (2016-2017)<br />
133 Boehringer Ingelheim International GmbH:<br />
Global Presence<br />
134 Boehringer Ingelheim International GmbH:<br />
SWOT Analysis<br />
135 BRISTOL-MYERS SQUIBB COMPANY: Overall<br />
Product Portfolio<br />
136 BRISTOL-MYERS SQUIBB COMPANY: Product<br />
Portfolio for <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong><br />
137 BRISTOL-MYERS SQUIBB COMPANY: Overall<br />
Financials (2014-2017)<br />
138 BRISTOL-MYERS SQUIBB COMPANY: Revenue by<br />
Geography (2014-2017)<br />
139 BRISTOL-MYERS SQUIBB COMPANY: Global<br />
Presence<br />
140 BRISTOL-MYERS SQUIBB COMPANY: SWOT<br />
Analysis<br />
141 CELGENE CORPORATION: Overall Product<br />
Portfolio<br />
142 CELGENE CORPORATION: Product Portfolio for<br />
<strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong><br />
143 CELGENE CORPORATION: Overall Financials<br />
(2014-2017)<br />
144 CELGENE CORPORATION: Revenue by<br />
Geography (2014-2017)<br />
145 CELGENE CORPORATION: Global Presence<br />
146 CELGENE CORPORATION: SWOT Analysis<br />
147 Eli-Lilly and Company: Overall Product Portfolio<br />
148 Eli-Lilly and Company: Product Portfolio for<br />
<strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong><br />
149 Eli-Lilly and Company: Overall Financials (2014-<br />
2017)<br />
150 Eli-Lilly and Company: Revenue by Business<br />
segment (2014-2017)<br />
151 Eli-Lilly and Company: Revenue by Geography<br />
(2014-2017)<br />
152 Eli-Lilly and Company: Global Presence<br />
153 Eli-Lilly and Company: SWOT Analysis<br />
154 F. Hoffmann-La Roche AG: Overall Product<br />
Portfolio<br />
sales@bisresearch.com www.bisresearch.com 6
155 F. Hoffmann-La Roche AG: Product Portfolio for<br />
<strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong><br />
156 F. Hoffmann-La Roche AG: Overall Financials<br />
(2014-2017)<br />
157 F. Hoffmann-La Roche AG: Product Sales by<br />
Region (2014-2017)<br />
158 F. Hoffmann-La Roche AG: Revenue by Division<br />
(2014-2017)<br />
159 F. Hoffmann-La Roche AG: Revenue by<br />
Pharmaceutical Sub-Segment (2014-2017)<br />
160 F. Hoffmann-La Roche AG: Global Presence<br />
161 F. Hoffmann-La Roche AG: SWOT Analysis<br />
162 JOHNSON & JOHNSON: Overall Product Portfolio<br />
163 JOHNSON & JOHNSON: Product Portfolio for<br />
<strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong><br />
164 JOHNSON & JOHNSON: Overall Financials (2014-<br />
2017)<br />
165 JOHNSON & JOHNSON: Revenue by Business<br />
segment (2014-2017)<br />
166 JOHNSON & JOHNSON: Revenue by Geography<br />
(2014-2017)<br />
167 JOHNSON & JOHNSON: Global Presence<br />
168 JOHNSON & JOHNSON: SWOT Analysis<br />
169 Merck & Co., Inc.: Overall Product Portfolio<br />
170 Merck & Co., Inc.: Product Portfolio for <strong>Metastatic</strong><br />
<strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong><br />
171 Merck & Co., Inc.: Overall Financials (2014-2017)<br />
172 Merck & Co., Inc.: Revenue by Business segment<br />
(2014-2017)<br />
173 Merck & Co., Inc.: Revenue by Geography (2014-<br />
2017)<br />
174 Merck & Co., Inc.: Global Presence<br />
175 Merck & Co., Inc.: SWOT Analysis<br />
176 Novartis AG: Overall Product Portfolio<br />
177 Novartis AG: Product Portfolio for <strong>Metastatic</strong><br />
<strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong><br />
178 Novartis AG: Overall Financials (2014-2017)<br />
179 Novartis AG: Revenue by Geography (2014-2017)<br />
180 Novartis AG: Revenue by Business Segment<br />
(2014-2015)<br />
181 Novartis AG: Revenue by Buisness Segment<br />
(2016-2017)<br />
182 Novartis AG: Global Presence<br />
183 Novartis AG: SWOT Analysis<br />
184 Pfizer, Inc.: Overall Product Portfolio<br />
185 Pfizer, Inc.: Product Portfolio for <strong>Metastatic</strong><br />
<strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong><br />
186 Pfizer, Inc.: Overall Financials (2014-2017)<br />
187 Pfizer, Inc.: Revenue by Business segment (2014-<br />
2017)<br />
188 Pfizer, Inc.: Revenue by Geography (2014-2017)<br />
189 Pfizer, Inc.: Global Presence<br />
190 Pfizer, Inc.: SWOT Analysis<br />
191 SANOFI: Overall Product Portfolio<br />
192 SANOFI: Product Portfolio for <strong>Metastatic</strong> <strong>Cancer</strong><br />
<strong>Treatment</strong> <strong>Market</strong><br />
193 SANOFI: Overall Financials (2014-2017)<br />
194 SANOFI: Revenue by Business Segment (2014-<br />
2015)<br />
195 SANOFI: Revenue by Business Segment (2016-<br />
2017)<br />
196 SANOFI: Revenue by Geography (2014-2015)<br />
197 SANOFI: Revenue by Geography (2016-2017)<br />
198 SANOFI: Global Presence<br />
199 SANOFI: SWOT Analysis<br />
200 Takeda Pharmaceutical Company Limited: Overall<br />
Product Portfolio<br />
201 Takeda Pharmaceutical Company Limited: Product<br />
Portfolio for <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong><br />
202 Takeda Pharmaceutical Company Limited: Overall<br />
Financials (2014-2017)<br />
203 Takeda Pharmaceutical Company Limited:<br />
Revenue by Business segment (2014-2017)<br />
204 Takeda Pharmaceutical Company Limited:<br />
Revenue by Geography (2014-2017)<br />
205 Takeda Pharmaceutical Company Limited: Global<br />
Presence<br />
206 Takeda Pharmaceutical Company Limited: SWOT<br />
Analysis<br />
207 bluebird bio, Inc.: Product Pipeline for <strong>Cancer</strong><br />
<strong>Treatment</strong> <strong>Market</strong><br />
208 Clovis Oncology, Inc.: Product Pipeline for <strong>Cancer</strong><br />
<strong>Treatment</strong> <strong>Market</strong><br />
209 IDERA PHARMACEUTICALS, INC.: Product<br />
Pipeline for <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong><br />
210 eTheRNA immunotherapies NV: Product Pipeline<br />
for <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong><br />
211 Global <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong><br />
Segmentation<br />
212 Considered Factors for Data Prediction & Modeling<br />
sales@bisresearch.com www.bisresearch.com 7
1 Research Scope & BIS Methodology<br />
1.1 Scope of the Report<br />
The report comprises an in-depth study of the global metastatic cancer treatment market, including a<br />
thorough analysis of the various products across different regions. The study also presents a detailed<br />
analysis of the market dynamics and the estimation of the market size over the forecast period, from<br />
2018 to 2025. The scope of this report is focused on the global metastatic cancer treatment market,<br />
the different product segments, their market trends, and country-wise analysis. In the report, three<br />
categories have been considered. The market value may vary from 5-7%, as the data have been collected<br />
from different sources at regional and country levels.<br />
The market analysis includes an in-depth examination of the key ecosystem players and key strategies<br />
and developments taking place in this market. Additionally, it includes market dynamics (market drivers,<br />
opportunities, and challenges) and industry analysis. The purpose of the study is to gain a holistic view of<br />
the cancer treatment market in terms of various factors influencing it, such as, recent trends, technological<br />
advancements, and regulatory aspects of the market. The scope of this report is centred upon conducting<br />
a detailed study of the solutions allied with the metastatic cancer treatment market. The market has been<br />
segmented into ‘therapeutic indication, ‘product’, and ‘geographical regions’.<br />
1.2 BIS Research <strong>Market</strong> Research Methodology<br />
The research methodology design adopted for this specific study includes a mix of data collected from<br />
primary and secondary sources. Both primary sources (in-house experts, industry leaders, and market<br />
players) and secondary sources (a host of paid and unpaid databases) along with analytical tools have<br />
been used exhaustively to build the forecast and predictive models.<br />
sales@bisresearch.com www.bisresearch.com 8
Figure 1<br />
BIS Research <strong>Market</strong> Research Methodology<br />
• A prominent global B2B market intelligence and advisory firm<br />
• Publishes 150 premium market research reports annually<br />
• Unique positioning through specifically targeting high growth, niche<br />
markets, and technologies<br />
• 100+ analysts and SME continually tracking technology market<br />
• Proven expertise to provide business intelligence across the product<br />
technology lifecycle<br />
• Serves as an industry knowledge partner to Fortune 2000 companies and<br />
emerging companies across the globe<br />
BIS SERVICE PORTFOLIO<br />
<strong>Market</strong> Estimation and Forecast<br />
Competitive Intelligence and Profiling<br />
Go-to-<strong>Market</strong><br />
Trend Analysis<br />
OUR VISION<br />
Be a leading and a preferred knowledge<br />
partner for corporates and institutions<br />
worldwide and assist with market<br />
intelligence in the area of emerging<br />
technologies, advisory, and other innovative<br />
solutions<br />
OUR MISSION<br />
BIS OPERATES ACROSS THE FOLLOWING INDUSTRY VERTICALS<br />
3D Printing<br />
Building Technologies & HVAC<br />
Growth Opportunities<br />
Value Chain & <strong>Market</strong> Share Analysis<br />
Assist our client growth by providing indepth<br />
knowledge of products across<br />
emerging and high technology markets.<br />
Advanced Materials & Chemicals<br />
BIS Healthcare<br />
Regulatory Monitoring<br />
VALUE STATEMENT<br />
Aerospace & Defense<br />
Agriculture & Food Tech<br />
BIS Automotive<br />
Electronics & Semiconductor<br />
Robotics & UAV<br />
Security & Surveillance<br />
Expert Interviews<br />
Business Intelligence Services<br />
Technology Landscape<br />
Customer First Always<br />
Professionalism in our work,<br />
experimentation, and innovation is what<br />
drives us everyday.<br />
BIS Research Analysis<br />
Primary Data Sources<br />
The key data points taken from the primary sources include:<br />
• Validation and Triangulation of all the numbers and graphs<br />
• Validation of report segmentation and key qualitative findings<br />
• Understanding the competitive landscape<br />
• Understanding and considering the factors for market dynamics of various market segments and subsegments<br />
• Validation of impact analysis of macro and micro factors in different countries<br />
• Percentage split of individual markets for geographical analysi<br />
Secondary Data Sources<br />
The research study involves the usage of extensive secondary sources such as databases, company<br />
websites, and annual reports, among others.<br />
sales@bisresearch.com www.bisresearch.com 9
The following figure exhibits key secondary data sources considered in this report:<br />
Figure 2<br />
Secondary Data Sources<br />
STOCK ANALYST WEBSITES<br />
COMPANY SOURCES<br />
Seeking Alpha<br />
Yahoo Finance<br />
Wiki Finance<br />
The Wall Street Journal<br />
Annual Reports<br />
Press Releases<br />
Sec Filings<br />
Investor Presentations<br />
Financial Disclosures<br />
SECONDARY DATA SOURCES<br />
GOVERNMENT AND REGULATORY SOURCES<br />
Centers for Disease Control and Prevention (CDC)<br />
The World Health Organisation (WHO)<br />
The National Health Services (NHS)<br />
The National Center for Biotechnology Infromation (NCBI)<br />
The Food & Drug Administration of United States (U.S. FDA)<br />
PUBLIC AND PRIVATE DATABASES<br />
Medline<br />
PubMed<br />
National Library of Medicine<br />
ProQuest<br />
CMS Database<br />
Medicare Beneficiary Database<br />
Oxon Epidemiology<br />
BIS Research Analysis<br />
The key data points taken from the secondary sources include:<br />
• Segmentation breakups, split-ups, and percentage shares<br />
• Data for market value<br />
• Key industry trends of the top players of the market<br />
• Qualitative insights into various aspects of the market, key trends, and emerging areas of<br />
innovation<br />
• Quantitative data for mathematical and statistical calculations<br />
sales@bisresearch.com www.bisresearch.com 10
The following figure exhibits data triangulation considered:<br />
Figure 3<br />
Data Triangulation<br />
Primary Sources<br />
Qualitative and Quantitative data<br />
collected from interviews<br />
conducted with senior management<br />
personnel from renowned<br />
companies and industry experts<br />
Data Analysis<br />
The data collected from primary<br />
a nd s econdary s ources is va lidated a nd a nalyzed to arri ve at<br />
a market size through top-down or bottom-up a pproach<br />
Secondary Sources<br />
Qualitative data collected from reliable<br />
sources, white papers, e-magazines,<br />
government records, and trade data<br />
BIS Research Analysis<br />
REQUEST FOR<br />
SAMPLE<br />
sales@bisresearch.com www.bisresearch.com 11
Change language